Dr. Felix Sheinerman received his Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute, La Jolla, CA, for his work on protein folding, and completed Alfred P. Sloan Foundation Postdoctoral Fellowship in Computational Biology at Columbia University, New York, working on modeling of protein-protein interactions and on comparative analysis of ligand-binding properties of structurally related proteins. In 2001 Felix joined Aventis (later: sanofi-aventis), where he worked in informatics and chemistry departments, supporting a large number of drug discovery projects across different therapeutic areas and stages.
In 2008 Felix left sanofi-aventis to co-found nPharmakon, a life sciences company that pioneered drug retargeting. Serving as Chief Scientific Officer at the company, Felix led the development of novel computational methods for identification of molecular targets and therapeutic indications for clinically tested small molecules. Using the methods developed at the company, Felix and his colleagues successfully identified leads and candidates for major poorly addressed indications in CNS, oncology, and dermatology, taking one molecule from discovery of a novel target and pre-clinical characterization to proof-of-principle data in a double-blind clinical efficacy study. In 2016, Felix also worked with Lodo Therapeutics, the Gates foundation backed biotech company, on the development of the chemogenomics workflow for identifying new therapeutic uses of bacterially produced products.
In 2017 Felix joined the Trudeau Institute to spearhead the discovery of small molecule tools, leads, and drug candidates against M. tuberculosis and other pathogens impervious to current therapy.